X-Linked Hypophosphatemia
FDA approves burosumab for tumor-induced osteomalacia
The FDA approved burosumab-twza injection to treat patients aged 2 years and older with tumor-induced osteomalacia, according to an agency press release.
Burosumab improves bone healing, quality of life in tumor-induced osteomalacia
A small cohort of adults with tumor-induced osteomalacia experienced improvements in phosphate and skeletal metabolism, physical functioning and quality of life after 144 weeks of treatment with burosumab therapy, study data show.
Musculoskeletal abnormalities common in adult X-linked hypophosphatemia
Abnormal bony projections in joint spaces and at attachments of tendons or ligaments were common among a small cohort of middle-aged adults with X-linked hypophosphatemia, progressively impairing joint range of motion, gait and physical function and warranting a longitudinal care plan, according to findings published in The Journal of Clinical Endocrinology & Metabolism.